Published in J Rheumatol on March 01, 1999
Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis (2003) 3.33
Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis (2004) 2.08
Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis (2007) 1.86
Long term high intensity exercise and damage of small joints in rheumatoid arthritis. Ann Rheum Dis (2004) 1.73
Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. Ann Rheum Dis (2003) 1.54
Infliximab in active early rheumatoid arthritis. Ann Rheum Dis (2004) 1.47
Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis (2007) 1.43
Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis (2002) 1.38
Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages. Ann Rheum Dis (2001) 1.37
The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis (2006) 1.24
Radiological damage in patients with rheumatoid arthritis on sustained remission. Ann Rheum Dis (2006) 1.16
Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol (2009) 1.10
Determining the clinical importance of treatment benefits for interventions for painful orthopedic conditions. J Orthop Surg Res (2015) 1.07
Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Ann Rheum Dis (2008) 0.96
Imaging: do erosions heal? Ann Rheum Dis (2003) 0.92
Relationship between time-integrated disease activity estimated by DAS28-CRP and radiographic progression of anatomical damage in patients with early rheumatoid arthritis. BMC Musculoskelet Disord (2011) 0.89
Long-term follow-up of a high-intensity exercise program in patients with rheumatoid arthritis. Clin Rheumatol (2009) 0.83
Quantitative in vivo HR-pQCT imaging of 3D wrist and metacarpophalangeal joint space width in rheumatoid arthritis. Ann Biomed Eng (2013) 0.82
Long term efficacy and safety of cyclosporin versus parenteral gold in early rheumatoid arthritis: a three year study of radiographic progression, renal function, and arterial hypertension. Ann Rheum Dis (2002) 0.82
Profile and course of early rheumatoid arthritis in Morocco: a two-year follow-up study. BMC Musculoskelet Disord (2011) 0.80
Structural damage in rheumatoid arthritis as visualized through radiographs. Arthritis Res (2002) 0.77
Using Dermal Temperature to Identify Rheumatoid Arthritis Patients With Radiologic Progressive Disease in Less Than One Minute. Arthritis Care Res (Hoboken) (2016) 0.75
[Computer assisted radiological diagnostics of arthritic joint alterations]. Z Rheumatol (2006) 0.75
American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum (1995) 15.00
The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum (1993) 8.73
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis (2009) 8.37
The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol (1998) 7.43
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet (1997) 6.71
The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis (2010) 5.24
Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol (1997) 5.09
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2011) 4.78
Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum (2001) 4.57
The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis (2009) 4.37
ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2005) 4.31
OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage (2004) 4.01
Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis (2004) 3.95
The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol (1998) 3.75
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis (2008) 3.45
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 3.17
Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis (2009) 3.15
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum (2004) 3.00
Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum (2000) 2.92
How to diagnose axial spondyloarthritis early. Ann Rheum Dis (2004) 2.91
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis (2003) 2.85
Evidence for a specific B27-associated cell surface marker on lymphocytes of patients with ankylosing spondylitis. Nature (1979) 2.79
Combination therapy in rheumatoid arthritis: updated systematic review. Br J Rheumatol (1998) 2.77
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
OMERACT conference on outcome measures in rheumatoid arthritis clinical trials: introduction. J Rheumatol (1993) 2.74
Ankylosing spondylitis: an overview. Ann Rheum Dis (2002) 2.71
Ecological genomics of marine Roseobacters. Appl Environ Microbiol (2007) 2.68
Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis (2008) 2.61
Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. Ann Rheum Dis (2004) 2.60
ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol (1999) 2.58
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
A factor(s) in Klebsiella culture filtrates specifically modifies an HLA-B27 associated cell-surface component. Nature (1980) 2.49
Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis (2005) 2.48
Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis (2003) 2.48
Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative. Osteoarthritis Cartilage (2000) 2.42
Outcome of out-of-hospital cardiac or respiratory arrest in children. N Engl J Med (1996) 2.29
New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis (2009) 2.22
Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol (1999) 2.21
First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis (2005) 2.21
Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. J Rheumatol (1993) 2.14
Systemic lupus erythematosus. A prospective analysis. Ann Rheum Dis (1978) 2.12
Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis (2004) 2.08
Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis (2003) 2.03
Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis (2002) 2.02
Physical therapy is effective for patients with osteoarthritis of the knee: a randomized controlled clinical trial. J Rheumatol (2001) 1.95
Minimal clinically important differences: review of methods. J Rheumatol (2001) 1.94
Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev (2007) 1.91
Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis (2003) 1.91
EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis (2007) 1.90
An introduction to the EULAR-OMERACT rheumatoid arthritis MRI reference image atlas. Ann Rheum Dis (2005) 1.89
High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis (2007) 1.87
Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage. Arthritis Rheum (2002) 1.87
Neonatal follow-up of very low birthweight/extremely low birthweight infants to school age: a critical overview. Acta Paediatr Scand (1992) 1.87
Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum (2001) 1.86
Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis (2005) 1.85
Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis (2002) 1.85
Second primary tumors in hereditary retinoblastoma: a register-based study, 1945-1997: is there an age effect on radiation-related risk? Ophthalmology (2001) 1.85
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis (2013) 1.81
Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis (2001) 1.77
Differences in descriptions of Kellgren and Lawrence grades of knee osteoarthritis. Ann Rheum Dis (2008) 1.73
Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis (2008) 1.73
Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis (2009) 1.72
Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis (2005) 1.70
The art of quality assessment of RCTs included in systematic reviews. J Clin Epidemiol (2001) 1.69
Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum (2001) 1.68
Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann Rheum Dis (2003) 1.66
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum (2008) 1.66
Looking for important change/differences in studies of responsiveness. OMERACT MCID Working Group. Outcome Measures in Rheumatology. Minimal Clinically Important Difference. J Rheumatol (2001) 1.64
Cortical hand bone loss after 1 year in early rheumatoid arthritis predicts radiographic hand joint damage at 5-year and 10-year follow-up. Ann Rheum Dis (2008) 1.60
Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. Ann Rheum Dis (2005) 1.59
Disease activity and health status in rheumatoid arthritis: a case-control comparison between Norway and Lithuania. Ann Rheum Dis (2003) 1.58
Reliability and validity of the EuroQol in patients with osteoarthritis of the knee. Rheumatology (Oxford) (1999) 1.58
Reading radiographs in chronological order, in pairs or as single films has important implications for the discriminative power of rheumatoid arthritis clinical trials. Rheumatology (Oxford) (1999) 1.57
Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. Ann Rheum Dis (2004) 1.56
Follow-up study of juvenile chronic polyarthritis with particular reference to histocompatibility antigen W. 27. Ann Rheum Dis (1974) 1.55
The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument. Br J Rheumatol (1997) 1.55
Development of a questionnaire to investigate patient compliance with antirheumatic drug therapy. J Rheumatol (1999) 1.54
Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis (2004) 1.53
Quality of life in rheumatoid arthritis. Br J Rheumatol (1997) 1.52
Validity of the MACTAR questionnaire as a functional index in a rheumatoid arthritis clinical trial. The McMaster Toronto Arthritis. J Rheumatol (2000) 1.51
Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences. Ann Rheum Dis (2005) 1.51
Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis (2008) 1.50
Subclinical renal dysfunction is independently associated with cardiovascular events in rheumatoid arthritis: the CARRÉ Study. Ann Rheum Dis (2011) 1.50
Comparing morphometric X-ray absorptiometry and radiography in defining vertebral wedge fractures in patients with ankylosing spondylitis. Rheumatology (Oxford) (2007) 1.49
Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis. Ann Rheum Dis (2004) 1.49
Do we need randomised trials to evaluate diagnostic procedures? For. Eur J Nucl Med Mol Imaging (2003) 1.48
Radiographic assessment of sacroiliitis by radiologists and rheumatologists: does training improve quality? Ann Rheum Dis (2003) 1.46
Imaging and scoring in ankylosing spondylitis. Best Pract Res Clin Rheumatol (2002) 1.44
Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann Rheum Dis (2008) 1.44
Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis (2007) 1.44
Better guidelines to rheumatoid arthritis therapy. Aust N Z J Med (1993) 1.41